(E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
Racura Oncology identified the mechanism of action for its lead asset (E,E)-bisantrene, showing it binds to G4-DNA structures to silence c-MYC expression. The findings, presented at the AACR Annual Meeting, highlight the drug's potential as a best-in-class therapy targeting the MYC oncogene, a driver deregulated in many human cancers.
Key figures
- Drug Name
- (E,E)-bisantrene
- Phase Of Trial
- Phase 3
- Target
- c-MYC oncogene
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.